SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
160902
Phase 3 mab completed
Quick answer
SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) for Primary Immunodeficiency Diseases (PID) is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Primary Immunodeficiency Diseases (PID)
- Phase
- Phase 3
- Modality
- mab
- Status
- completed